Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $739197.0.

  • UroGen Pharma's Gains from Investment Securities fell 6012.94% to $739197.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $739197.0, marking a year-over-year decrease of 6012.94%. This contributed to the annual value of $200000.0 for FY2024, which is 8019.04% down from last year.
  • Latest data reveals that UroGen Pharma reported Gains from Investment Securities of $739197.0 as of Q3 2025, which was down 6012.94% from $767228.0 recorded in Q2 2025.
  • UroGen Pharma's 5-year Gains from Investment Securities high stood at $1.9 million for Q3 2024, and its period low was -$553000.0 during Q4 2021.
  • Its 5-year average for Gains from Investment Securities is $691401.9, with a median of $753212.5 in 2025.
  • In the last 5 years, UroGen Pharma's Gains from Investment Securities surged by 1016000.0% in 2021 and then tumbled by 15655.45% in 2025.
  • Quarter analysis of 5 years shows UroGen Pharma's Gains from Investment Securities stood at -$553000.0 in 2021, then surged by 148.64% to $269000.0 in 2022, then crashed by 104.46% to -$12000.0 in 2023, then surged by 1925.0% to $219000.0 in 2024, then surged by 237.53% to $739197.0 in 2025.
  • Its Gains from Investment Securities stands at $739197.0 for Q3 2025, versus $767228.0 for Q2 2025 and -$218000.0 for Q1 2025.